Our data suggest that the repurposing of existing FDA-approved PDE-Is for adjunctive TB chemotherapy could shorten treatment duration in TB patients, which would significantly impact in the global struggle against TB. The gene discussed is ALDH7A1; the disease is tuberculosis.